 |
236 Diseases |  |
42 Trials |
|
42 Trials |  |
3908 News |  |
| «12345678910111213...4849» |
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Journal: Shielding against breast tumor relapse with an autologous chemo-photo-immune active Nano-Micro-Sera based fibrin implant. (Pubmed Central) - Jul 26, 2024
While localized monotherapy with either Lap-NS or PNS reduced the tumor regrowth rate, their combination with IMQ-MS amplified the effect of immunogenic cell death with a high level of tumor infiltration by immune cells at the surgical site. The localized combination immunotherapy with a Nano-MicroSera based hybrid fibrin implant showed superior tumor inhibition and survival with significant promise for clinical translation.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Elucidation of Trastuzumab-Deruxtecan Resistance Mechanisms using in Vivo Xenograft Model Reflecting Pharmacokinetics (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1732;
In addition, the three resistant tumor cell lines expressed HER2 at the same level as each parental cell line, and were sensitive to afatinib and lapatinib, which have HER2 kinase inhibitory activity...Conclusions : These results suggest that the mechanism of T-Dxd resistance differs depending on the cancer type. We are currently conducting studies to further elucidate the resistance mechanism of T-Dxd in order to develop treatments to overcome resistance.
- | lapatinib / Generic mfg., paclitaxel / Generic mfg.
Journal, Metastases: Matrix stiffness influences response to chemo and targeted therapy in brain metastatic breast cancer cells. (Pubmed Central) - Jul 23, 2024
Accordingly, SGK1 inhibition resulted in a dormant-to-proliferative switch and response to therapy. Overall, our study demonstrates that matrix stiffness influences dormancy-associated therapy response mediated, in part, via the p38/SGK1 axis.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, HEOR: Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka. (Pubmed Central) - Jul 21, 2024
Even though only the ICER for strategy 3 was cost-effective, uncertainty of efficacy parameter was revealed. For strategy 2 neoadjuvant PTC plus adjuvant T, a 25% reduction of neoadjuvant regimen cost was required to be cost effective for use in early HER2 positive breast cancer.
- | Nerlynx (neratinib) / Puma
Journal: DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. (Pubmed Central) - Jul 15, 2024
In vivo, genetic targeting of DUSP6 reduced tumor growth in brain metastasis model, whereas its pharmacological targeting induced synthetic lethal therapeutic effect in combination with HER2i. Collectively this work demonstrates that DUSP6 drives escape from HER2i-induced dormancy, and that DUSP6 is a druggable target to overcome HER3-driven TKI resistance.
- | lapatinib / Generic mfg.
Journal: ErbB2-NOTCH1 axis controls autophagy in cardiac cells. (Pubmed Central) - Jul 12, 2024
Overexpression of ErbB2 in H9c2 cardiomyoblasts induced Notch1 activation in a post-transcriptional, p38-dependent manner, while ErbB2 inhibition with the specific inhibitor, lapatinib, reduced Notch1 activation...Furthermore, the hearts of transgenic mice specifically overexpressing ErbB2 in cardiomyocytes had increased levels of active Notch1 and of Notch-related genes. These data expand the knowledge of ErbB2 and Notch1 functions in the heart and may allow better understanding the mechanisms of the cardiotoxicity of ErbB2-targeting cancer treatments.
- || Review, Journal, Metastases: Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer. (Pubmed Central) - Jul 12, 2024
Antibo-drug conjugate, such as T-DM1 and T-DXd, can overcome the resistance of monoclonal antibodies despite their different mechanisms of tumor killing, and are a supplement for the treatment of patients who have failed the treatment of monoclonal antibodies such as trastuzumab. Therefore, after more detailed stratification of gastric cancer patients, various gastric cancer drugs targeting HER2 are expected to play a more significant role.
- | lapatinib / Generic mfg.
Journal, IO biomarker: Identification of disulfidptosis-related clusters and construction of a disulfidptosis-related gene prognostic signature in triple-negative breast cancer. (Pubmed Central) - Jul 12, 2024
Two TNBC clusters linked to disulfidptosis were identified, with different OS and immune cell infiltration. Moreover, a five-disulfidptosis-related gene signature may be a powerful prognostic biomarker for TNBC.
- | lapatinib / Generic mfg.
Journal: Novel dihydropyrimidines as promising EGFR & HER2 inhibitors: Insights from experimental and computational studies. (Pubmed Central) - Jul 10, 2024
These 3 compounds were subjected to flow cytometry studies and EGFRwt Kinase inhibition assay using lapatinib as a standard...Molecular docking studies were performed to validate the results by in silico method. All together, we developed a new series of Biginelli dihydropyrimidines as dual EGFR/HER2 inhibitors.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Preclinical, Review, Journal: Mechanisms of Acquired Resistance to HER2-Positive Breast Cancer Therapies Induced by HER3: A Comprehensive Review. (Pubmed Central) - Jul 1, 2024
The review also explores the resistance mechanisms associated with various drugs, including trastuzumab, lapatinib, and PI3K inhibitors, providing insights into the intricate molecular processes underlying resistance development. The review concludes by emphasizing the necessity for further clinical trials to assess the efficacy of HER3 inhibitors and the potential of developing safe and effective anti-HER3 treatments to improve treatment outcomes for patients with HER2-positive breast cancer.
- | lapatinib / Generic mfg.
Journal: A Lipophilic Salt Form to Enhance the Lipid Solubility and Certain Biopharmaceutical Properties of Lapatinib. (Pubmed Central) - Jun 27, 2024
A cytotoxicity study of LTP-DOC salt showed an approximately 2.5 times lower IC50 value than the LTP-free base and 1.7 times lower than commercial ditosylate salt with an approximately 3 times higher selectivity index. The investigations strongly indicate a high translational potential of the prepared salt form in maintaining solubility-lipophilicity interplay, enhancing the drug's bioavailability, and developing lipidic formulations.
- | Journal, IO biomarker: Stem cell index-based RiskScore model for predicting prognosis in thyroid cancer and experimental verification. (Pubmed Central) - Jun 13, 2024
Good performance of this model was validated in Test dataset, pan-cancer and immunotherapy datasets. This study identified three subtypes for classification and developed a prognostic model with mRNAsi-related genes, which provided great potential for prognosis and immunotherapy prediction.
- ||| oxaliplatin / Generic mfg., lapatinib / Generic mfg., capecitabine / Generic mfg.
Trial completion date, Metastases: LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib (clinicaltrials.gov) - Jun 12, 2024
P3, N=545, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
This study identified three subtypes for classification and developed a prognostic model with mRNAsi-related genes, which provided great potential for prognosis and immunotherapy prediction. Trial completion date: Aug 2024 --> Jan 2025
- | lapatinib / Generic mfg., paclitaxel / Generic mfg.
Journal, Tumor cell: pH-responsive drug-loaded peptides enhance drug accumulation and promote apoptosis in tumor cells. (Pubmed Central) - Jun 6, 2024
Ultimately, PL/Pep1 inhibited tumor angiogenesis and enhanced tumor cell apoptosis. The use of shape-changing peptides as drug carriers to enhance cancer cell apoptosis is promising.
- | lapatinib / Generic mfg.
Preclinical, Journal, Metastases: Laminin I mediates resistance to lapatinib in HER2-positive brain metastatic breast cancer cells in vitro. (Pubmed Central) - Jun 3, 2024
Laminin I also significantly enhanced the migratory potential and replicative viability of HER2-positive BMBC cells. In sum, our findings show that presence of Laminin I in the TME of BMBC cells imparts resistance to targeted therapeutic agent Lapatinib, while increasing the possibility of its dispersal and clonogenic survival.
- | Journal: Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic? (Pubmed Central) - Jun 1, 2024
Some of those, have not been associated with clinical cardiotoxicity, while others, known to be cardiotoxic do not appear to mediate it via direct effects on cardiomyocytes. More detailed investigations of the effects of cancer therapies on various cardiovascular cells should be performed to comprehensively determine the mechanisms of cardiotoxicity.
- | lapatinib / Generic mfg.
Journal, IO biomarker: Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps". (Pubmed Central) - May 30, 2024
In this study, lapatinib-resistant cells were used to test the concept of "Evolutionary Traps" and no suitable target stand out because of the identified genes without accessible drug...To test whether this concept is cell line or drug dependent, we analyzed 21 drug-resistant tumor cell expression profiles reveal that JAG1, GPC3, and L1CAM, which are suitable targets for CAR-T treatment, are significantly upregulated in various drug-resistant tumor cells. Our findings shed light on the feasibility of utilizing CAR-T therapy to treat drug-resistant tumors and broaden the concept of the "Evolutionary Trap".
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Review, Journal: Revolutionizing non-melanoma skin cancer treatment: Receptor tyrosine kinase inhibitors take the stage. (Pubmed Central) - May 30, 2024
Other RTKIs were only employed in experimental investigations. Research indicates that RTKIs could potentially serve as a suitable alternative for elderly patients who are unable to undergo chemotherapy and radiotherapy.
- | silmitasertib (CX-4945) / Senhwa Biosci, University of California
Journal: Bioinformatics analysis and experimental verification of the cancer-promoting effect of DHODH in clear cell renal cell carcinoma. (Pubmed Central) - May 26, 2024
Several drugs, such as lapatinib, silmitasertib, itraconazole, and dasatinib, were sensitive to DHODH expression and exhibited strong molecular binding with it. Thus, DHODH may promote ccRCC progression and is a candidate effective therapeutic target for ccRCC.
- | Votrient (pazopanib) / Novartis, BeiGene
Journal, Tumor mutational burden, IO biomarker: Molecular characterization, clinical value, and cancer-immune interactions of genes related to disulfidptosis and ferroptosis in colorectal cancer. (Pubmed Central) - May 24, 2024
In conclusion, SRF can act as a new biomarker for prognosis assessment. Moreover, it is also a good predictor of drug sensitivity and immunotherapy response in CRC but should undergo optimization before implementation in clinical settings.
- | Xalkori (crizotinib) / Pfizer, Gilotrif (afatinib) / Boehringer Ingelheim
Journal, Immunogenic cell death, IO biomarker: Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing to Identify an Immunogenic Cell Death-Related 5-Gene Prognostic Signature in Hepatocellular Carcinoma. (Pubmed Central) - May 21, 2024
Moreover, NKX3-2 amplification in HCC samples has been verified by experiments, and its disruption suppressed the proliferation and invasion of tumor cells. Our study highlighted the potential of the ICDRGs risk score as a prognostic indicator to aid in the accurate diagnosis and immunotherapy sensitivity of HCC.
- | miransertib (MK-7075) / Merck (MSD), Ibrance (palbociclib) / Pfizer, Nerlynx (neratinib) / Puma
Journal, Combination therapy: Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells. (Pubmed Central) - May 16, 2024
Notably, we found that treatment with neratinib in combination with palbociclib (CDK4/6 inhibitor), or miransertib (AKT1/2/3 inhibitor) resulted in synergistic growth inhibition of all HBCCLs. Our results support that repurposing drugs like neratinib in combination with the palbociclib or miransertib may be of therapeutic potential in brain cancer and warrants further investigations.
- || lapatinib / Generic mfg., temozolomide / Generic mfg.
Trial completion, Trial completion date, Combination therapy: Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - May 15, 2024
P2, N=50, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Our results support that repurposing drugs like neratinib in combination with the palbociclib or miransertib may be of therapeutic potential in brain cancer and warrants further investigations. Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> May 2024
- | lapatinib / Generic mfg.
Preclinical, Journal: Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: Modulation of dopamine D3 receptor. (Pubmed Central) - May 9, 2024
Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> May 2024 In the present study, 100
- || Review, Journal, Metastases: HER2-Positive Metastatic Colorectal Cancer. (Pubmed Central) - May 9, 2024
Trastuzumab plus lapatinib, trastuzumab plus pertuzumab, and trastuzumab deruxtecan (T-DXd) also have evidence of efficacy in this setting...These include the optimal sequence of anti-HER2 therapies with chemotherapy and anti-EGFR therapies, the optimal combination partners for anti-HER2 therapies, and the incorporation of predictive biomarkers to guide use of anti-HER2 therapies. Results of ongoing studies may thus alter the treatment paradigm above in the coming years.
- | Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol. (Pubmed Central) - May 1, 2024
Additionally, they provide a brief overview of novel systemic strategies such as adoptive cell transfer (CAR-T and NK cells), oncolytic viruses, epigenetic targeting (KDM6, HDAC, and EZH2 inhibitors), and several promising preclinical studies with high translational potential. Finally, the authors present their institutional multidisciplinary protocol for the incorporation of systemic therapy for both newly diagnosed and recurrent chordomas based on molecular studies including upfront enrollment in MTT trials in patients with epidermal growth factor receptor upregulation or INI-1 deficiency or enrollment in ICI clinical trials for patients with high tumor mutational burden or high PD-L1 expression on tumor cells or in the tumor microenvironment.
- | lapatinib / Generic mfg.
Journal, IO biomarker: Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression. (Pubmed Central) - Apr 29, 2024
Co-administration of EGF with lapatinib also restores the cell growth and cancels alteration of expression of 95.8% of the genes specific to lapatinib treatment of SK-BR-3 cells. Differential gene expression analysis also showed that in the presence of human serum or EGF, lapatinib was unable to inhibit the Toll-Like Receptor signaling pathway and alter expression of genes linked to the Gene Ontology term of Focal adhesion.
- | Retrospective data, Journal, Machine learning: A Radiogenomic multimodal and whole-transcriptome sequencing for preoperative prediction of axillary lymph node metastasis and drug therapeutic response in breast cancer: a retrospective, machine learning And international multi-cohort study. (Pubmed Central) - Apr 26, 2024
Overall, the radiogenomic multimodal model employs multimodal data, including radiological images, genetic, and clinicopathological typing. The radiogenomic multimodal nomogram can precisely predict ALNM and drug therapeutic response in BC patients.
- KW-2450 / Kyowa Kirin
Phase classification, Combination therapy, Metastases: Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 25, 2024
P1, N=11, Terminated, Sponsor: Kyowa Kirin Co., Ltd.
The radiogenomic multimodal nomogram can precisely predict ALNM and drug therapeutic response in BC patients. Phase classification: P1/2 --> P1
- anvatabart opadotin (JNJ-0683) / J&J, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6212;
5mg/kg combined with toripalimab was shown acceptable safety profile with promising efficacy, no significant increase in adverse reactions or serious unexpected immune-related adverse reactions compared with ARX788 monotherapy, which supports further evaluation for HER2-low ABC in a larger sample in ?b trial. Clinical trial information: CTR20222247.
- Kadcyla (ado-trastuzumab emtansine) / Roche
T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6138;
However, multivariate analysis suggested that previous exposure of pertuzumab did not affect the PFS of T-DM1, and patients with HER2 2+ and lung metastasis may not be the advantageous population for T-DM1 treatment. Thrombocytopenia was a dose-limiting toxicity of T-DM1, and most patients could tolerate it well after dose adjustment.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6136;
P2
The study will proceed to the second stage. Clinical trial information: NCT05560308.
- anvatabart opadotin (JNJ-0683) / J&J
ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2579;
ARX788 significantly prolonged PFS comparing to LC in patients with HER2+ ABC previously treated with trastuzumab and taxane. While ocular toxicity and interstitial lung disease were common and manageable, its hematological and GI toxicities under no prophylactic premedication compared favorably with already available ADCs.
- TQB2930 / Sino Biopharm
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study. (Hall A; Poster Bd #: 4) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2457;
P1/2
TQB2930 is well tolerated and has demonstrated promising single-agent anti-tumor activity in HER2-positive breast cancer who have failed standard anti-HER2 therapies, including multiple lines of prior HER2 targeted agents. These early signs of activity support the further exploration of combination therapy of TQB2930 and the study is ongoing.
- Herceptin (trastuzumab) / Roche
Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41. (S406) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2179;
P3
These findings can be partially explained by the mechanism of action of the HER2-directed agents. T leads to antibody-dependent cell-mediated cytotoxicity, and a higher percentage of TILs may enhance this mechanism, whereas L has intracellular tyrosine kinase disruption.
- | linsitinib (ASP7487) / Sling Therap
Journal: Investigating the Cell Origin and Liver Metastasis Factors of Colorectal Cancer by Single-Cell Transcriptome Analysis. (Pubmed Central) - Apr 22, 2024
Finally, in vitro experiments verified that silencing SOX4 significantly inhibited tumor cell migration and invasion. This study reveals the possible cellular origin and driving factors of LM in CRC at the single cell level, and provides a reference for early detection of CRC patients with a high risk of LM.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Review: Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses. (Pubmed Central) - Apr 18, 2024
Based on these findings, trastuzumab-containing regimens emerge as a preferable and recommended choice in clinical practice for managing HER2-positive breast cancer. PROSPERO, identifier CRD42023414348.
- || Review, Journal, PD(L)-1 Biomarker: Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice. (Pubmed Central) - Apr 17, 2024
Recently, the combination of trastuzumab with pembrolizumab, along with chemotherapy, and the development of trastuzumab deruxtecan, with its specific bystander activity, demonstrated improved outcomes, renewing attention in the treatment of this disease. This review will summarise historical and emerging therapies for the treatment of HER2-positive GEA, with a section dedicated to the HER2 molecular pathway and the use of novel blood biomarkers, such as circulating tumour DNA and circulating tumour cells, which may be helpful in the future to guide treatment decisions.
- | Journal: Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. (Pubmed Central) - Apr 15, 2024
This study aimed to develop and validate an LC-MS/MS method for the simultaneous quantification of 11 OADs (gefitinib, imatinib, lenvatinib, regorafenib, everolimus, osimertinib, sunitinib, tamoxifen, lapatinib, fruquintinib and sorafenib) and 2 active metabolites (N-desethyl sunitinib and Z-endoxifen) in human plasma. The intra- and inter-day imprecision was below 12.81
- | lapatinib / Generic mfg.
Journal: Identification of kinase modulators as host-directed therapeutics against intracellular methicillin-resistant Staphylococcus aureus. (Pubmed Central) - Apr 13, 2024
GW296115X activated adenosine monophosphate-activated protein kinase (AMPK), thereby enhancing bacterial degradation via autophagy. Finally, GW296115X not only reduced MRSA growth in human cells but also improved the survival rates of MRSA-infected zebrafish embryos, highlighting its potential as HDT.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Review, Journal: HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments. (Pubmed Central) - Apr 13, 2024
However, further improvements in HER2-directed therapy are required as resistance mechanisms and HER2 heterogeneity limit the existing treatment options. This review aims to give an overview of the current standard-of-care HER2-directed therapy in gastric cancer, as well as its challenges and future developments.
- | lapatinib / Generic mfg.
Journal: Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer via EGFR inhibition: molecular design, synthesis, analysis and screening. (Pubmed Central) - Apr 10, 2024
Based on the molecular docking study against EGFR, the most active derivatives HD-7 and HD-8 were docked against the active site of the protein and showed better binding affinity than the standard lapatinib. Additionally, molecular dynamics (MD) simulations were performed to explore the stability of the protein-ligand complex, its dynamic behavior, and the binding affinity.
- | Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Journal: Structural Perspectives in the Development of Novel EGFR Inhibitors for the Treatment of NSCLC. (Pubmed Central) - Apr 8, 2024
The review also includes various aspects of molecular docking studies with compounds under clinical trials and patents filed on pyrimidine-based EGFR inhibitors in treating non-small cell lung cancer. The present review may benefit the medicinal chemist for developing novel compounds such as EGFR inhibitors.
- | lapatinib / Generic mfg.
Journal: Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells. (Pubmed Central) - Apr 6, 2024
Prostate cancer cells insensitive to androgens may be resistant to lapatinib through PI3K gene dysregulation. The association of lapatinib with PI3K inhibitors may provide a more effective antitumor response and clinical benefits to PC patients.
- | IRX4204 / Io Therap
Journal: IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. (Pubmed Central) - Apr 5, 2024
These findings identify HER2 as a biomarker for IRX4204 treatment response and demonstrate a novel use of RXR agonists to synergize with current anti-HER2 therapies. Furthermore, our results suggest that RXR agonists can be useful for the treatment of anti-HER2 resistant and metastatic HER2-positive breast cancer.
- ||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Metastases: DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] (clinicaltrials.gov) - Apr 4, 2024
P3, N=608, Active, not recruiting, Sponsor: Daiichi Sankyo
Furthermore, our results suggest that RXR agonists can be useful for the treatment of anti-HER2 resistant and metastatic HER2-positive breast cancer. Trial completion date: Sep 2024 --> May 2025
- ||| oxaliplatin / Generic mfg., lapatinib / Generic mfg., capecitabine / Generic mfg.
Trial completion date, Metastases: LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib (clinicaltrials.gov) - Apr 4, 2024
P3, N=545, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2024 --> May 2025 Trial completion date: May 2024 --> Aug 2024
- || Herceptin (trastuzumab) / Roche
Retrospective data, Review, Journal: Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review. (Pubmed Central) - Apr 3, 2024
Increasing rates of BC-LMD provide treatment challenges and opportunities for clinical trials. Prospective trials testing lapatinib and/or similar tyrosine kinase inhibitors, IT therapies, and combination treatments are urgently needed.
- | lapatinib / Generic mfg.
Journal, Combination therapy: EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells. (Pubmed Central) - Apr 1, 2024
expression and Akt phosphorylation suppression. These results highlight the potential of this therapeutic approach as a promising strategy for managing HER2-positive breast cancer.
- | Prolia (denosumab) / Amgen, Kadcyla (ado-trastuzumab emtansine) / Roche
Journal, Metastases: Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports. (Pubmed Central) - Mar 29, 2024
It is possible that antitumor drugs affect calcium and bone metabolism associated with bone metastases. While these cases are rare, it is crucial for oncologists to be aware of hypocalcemia not only at the initiation of bone-modifying agents but also throughout the entire antitumor therapy, as hypocalcemia can lead to fatal outcomes.